Connect Biopharma Holdings Limited
CNTB
$0.80
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 958.50K | 958.50K | 12.06M | 12.06M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 958.50K | 958.50K | 12.06M | 12.06M | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 958.50K | 958.50K | 12.06M | 12.06M | -- |
| SG&A Expenses | 5.90M | 5.90M | 3.71M | 3.71M | 3.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.29M | 1.29M | -1.29M | -1.29M | 684.00K |
| Total Operating Expenses | 15.16M | 15.16M | 9.09M | 9.09M | 17.84M |
| Operating Income | -14.20M | -14.20M | 2.97M | 2.97M | -17.84M |
| Income Before Tax | -11.56M | -11.56M | 3.85M | 3.85M | -15.79M |
| Income Tax Expenses | 81.50K | 81.50K | 30.00K | 30.00K | 28.00K |
| Earnings from Continuing Operations | -11.64M | -11.64M | 3.82M | 3.82M | -15.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.64M | -11.64M | 3.82M | 3.82M | -15.82M |
| EBIT | -14.20M | -14.20M | 2.97M | 2.97M | -17.84M |
| EBITDA | -14.04M | -14.04M | 3.14M | 3.14M | -17.67M |
| EPS Basic | -0.21 | -0.21 | 0.07 | 0.07 | -0.29 |
| Normalized Basic EPS | -0.14 | -0.14 | 0.05 | 0.05 | -0.18 |
| EPS Diluted | -0.21 | -0.21 | 0.07 | 0.07 | -0.29 |
| Normalized Diluted EPS | -0.14 | -0.14 | 0.05 | 0.05 | -0.18 |
| Average Basic Shares Outstanding | 55.28M | 55.28M | 55.14M | 55.14M | 55.08M |
| Average Diluted Shares Outstanding | 55.28M | 55.28M | 55.55M | 55.55M | 55.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |